MENU
+Compare
IBB
ETF ticker: NASDAQ
AS OF
Mar 31, 01:01 PM (EDT)
Price
$126.97
Change
-$3.33 (-2.56%)
Net Assets
5.9B

IBB stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U... Show more

Category: #Health
IBB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for IBB with price predictions
Mar 28, 2025

IBB's Stochastic Oscillator is remaining in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in of 338 cases, the price rose further within the following month. The odds of a continued upward trend are .

IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on February 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

IBB moved below its 50-day moving average on March 10, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBB crossed bearishly below the 50-day moving average on March 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IBB entered a downward trend on March 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF ETF is 5.83B. The market cap for tickers in the group ranges from 24.88M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is OVID at 24.88M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF ETF was 32%. For the same ETF, the average monthly price growth was 65%, and the average quarterly price growth was 324%. TSHA experienced the highest price growth at 18%, while HUMA experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF ETF was -53%. For the same stocks of the ETF, the average monthly volume growth was -32% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 76
Price Growth Rating: 68
SMR Rating: 89
Profit Risk Rating: 85
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
IBB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com